Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07084311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
Trial Details
NCT Number NCT07084311
Lead Sponsor n-Lorem Foundation
Collaborators: Hawaii Pacific Neuroscience
Conditions
(from sponsor)		 Dentatorubral-Pallidoluysian Atrophy
Related terms Myoclonic Epilepsies, Progressive
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov